Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alkermes plc, Intellia Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alkermes plc, Intellia Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Alkermes plc, Intellia Therapeutics and Inc.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company’s in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Latest Biotechnology and Alkermes plc, Intellia Therapeutics, Inc. Stock News

As of September 10, 2026, Alkermes plc had a $7.7 billion market capitalization, compared to the Biotechnology median of $272.7 million. Alkermes plc’s stock is up 64.8% in 2026, down 3.4% in the previous five trading days and up 65.57% in the past year.

Currently, Alkermes plc’s price-earnings ratio is 118.8. Alkermes plc’s trailing 12-month revenue is $1.7 billion with a 4.0% net profit margin. Year-over-year quarterly sales growth most recently was 27.0%. Analysts expect adjusted earnings to reach $1.275 per share for the current fiscal year. Alkermes plc does not currently pay a dividend.

As of September 10, 2026, Intellia Therapeutics, Inc. had a $1.7 billion market cap, putting it in the 51st percentile of all stocks. Intellia Therapeutics, Inc.’s stock is up 32.7% in 2026, down 6.5% in the previous five trading days and up 0.42% in the past year.

Currently, Intellia Therapeutics, Inc. does not have a price-earnings ratio. Intellia Therapeutics, Inc.’s trailing 12-month revenue is $59.5 million with a -672.2% net profit margin. Year-over-year quarterly sales growth most recently was -45.8%. Analysts expect adjusted earnings to reach $-3.157 per share for the current fiscal year. Intellia Therapeutics, Inc. does not currently pay a dividend.

How We Compare Alkermes plc, Intellia Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alkermes plc, Intellia Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alkermes plc, Intellia Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Alkermes plc	ALKS	F
Intellia Therapeutics, Inc.	NTLA	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Alkermes plc has a Value Score of 11, which is Ultra Expensive. Intellia Therapeutics, Inc. has a Value Score of 9, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Alkermes plc, Intellia Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Alkermes plc, Intellia Therapeutics or Inc. is the better investment when it comes to value.

Alkermes plc, Intellia Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Alkermes plc	ALKS	B
Intellia Therapeutics, Inc.	NTLA	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alkermes plc has a Growth Score of 61, which is Strong. Intellia Therapeutics, Inc. has a Growth Score of 17, which is Very Weak.

The Growth Grade Winner: Alkermes plc

As you can clearly see from the Growth Grade breakdown above, Alkermes plc has a more attractive growth grade than Intellia Therapeutics, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Alkermes plc could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alkermes plc, Intellia Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Alkermes plc	ALKS	D
Intellia Therapeutics, Inc.	NTLA	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Alkermes plc has a Earnings Estimate Score of 32, which is Negative. Intellia Therapeutics, Inc. has a Earnings Estimate Score of 35, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Alkermes plc, Intellia Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Alkermes plc, Intellia Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Alkermes plc, Intellia Therapeutics and Inc. Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alkermes plc, Intellia Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alkermes plc, Intellia Therapeutics or Inc. Stock?

Overall, Alkermes plc stock has a Value Score of 11, Growth Score of 61 and Estimate Revisions Score of 32.

Intellia Therapeutics, Inc. stock has a Value Score of 9, Growth Score of 17 and Estimate Revisions Score of 35.

Comparing Alkermes plc, Intellia Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.